Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

hsa-miR-9-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

New RDM0050H 96 wells (1 kit)
PubMed Product Details
Technical Data


miREIA – miRNA enzyme immunoassay


Tissue extract, Cell culture lysate

Sample Requirements

10 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

12.5 – 0.39 amol/μl

Limit of Detection

0.13 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 5.7%

Inter-assay (Run-to-Run)

n = 5,
CV = 8.5%

Spiking Recovery


Dilution Linearity



Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.


Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.

Product Manual: miREIA - microRNA enzyme immunoassay




  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-9-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Autoimmunity, Oncology


MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-9-5p is expressed in various cell types, first in the central nervous system during embryonic development, and later in macrophages, neutrophils, and tumor cells. The expression level of miR-9-5p has been shown to have an association with various human cancers including breast cancer, gastric cancer, pancreatic cancer and glioblastoma.

miR-9 could regulate the expression of E-cadherin, a prominent molecule responsible for cell adhesion, in breast cancer cells. The expression level of miR-9-5p significantly decreased in the tissues of gastric cancer in comparison with normal tissues. There was also a reduction in the expression level of miR-9-5p in the serum of gastric cancer patients. miR-9-5p was significantly downregulated in pancreatic cancer tissues and cell lines. The expression levels of miR-9-5p were negatively correlated with tumor stage and vessel invasion. Low expression of miR-9-5p was strongly correlated with poor overall survival in pancreatic cancer patients. Moreover, overexpression of miR-9-5p remarkably inhibited pancreatic cancer cell proliferation by enhancing cell apoptosis and significantly suppressed the invasion of pancreatic cancer cells. Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma. miR-9 can reduce cell migration and the invasion of glioblastoma cell lines through MAPK14 pathway.

miR-9-5p has been reported to be upregulated and closely related to collagen proteins in human dermal fibroblasts. MiR-9-5p suppressed proliferation and promoted apoptosis of hypertrophic scar fibroblasts by targeting peroxisome proliferator-activated receptor β (PPARβ). In patients with rheumatoid arthritis (RA) and peripheral neuropathy, serum miR-9-5p was significantly downregulated when compared with serum samples from patient with RA. A significantly negative correlation was observed between miR-9-5p and repressor element-1 silencing transcription factor REST.

Summary References (7)

References to miR-9-5p

  • Ben-Hamo R, Zilberberg A, Cohen H, Efroni S. hsa-miR-9 controls the mobility behavior of glioblastoma cells via regulation of MAPK14 signaling elements. Oncotarget. 2016 Apr 26;7(17):23170-81. doi: 10.18632/oncotarget.6687. PMID: 27036038; PMCID: PMC5029618. See more on PubMed
  • Chai CY, Tai IC, Zhou R, Song J, Zhang C, Sun S. MicroRNA-9-5p inhibits proliferation and induces apoptosis of human hypertrophic scar fibroblasts through targeting peroxisome proliferator-activated receptor β. Biol Open. 2020 Dec 21;9(12):bio051904. doi: 10.1242/bio.051904. PMID: 33355167; PMCID: PMC7774882. See more on PubMed
  • Li Z, Li Y, Li Q, Zhang Z, Jiang L, Li X. Role of miR-9-5p in preventing peripheral neuropathy in patients with rheumatoid arthritis by targeting REST/miR-132 pathway. In Vitro Cell Dev Biol Anim. 2019 Jan;55(1):52-61. doi: 10.1007/s11626-018-0310-2. Epub 2018 Nov 19. PMID: 30456455. See more on PubMed
  • Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010 Mar;12(3):247-56. doi: 10.1038/ncb2024. Epub 2010 Feb 21. PMID: 20173740; PMCID: PMC2845545. See more on PubMed
  • Tavakolian S, Goudarzi H, Faghihloo E. Evaluating the expression level of miR-9-5p and miR-192-5p in gastrointestinal cancer: introducing novel screening biomarkers for patients. BMC Res Notes. 2020 Apr 19;13(1):226. doi: 10.1186/s13104-020-05071-9. PMID: 32307002; PMCID: PMC7168809. See more on PubMed
  • Wang J, Wang B, Ren H, Chen W. miR-9-5p inhibits pancreatic cancer cell proliferation, invasion and glutamine metabolism by targeting GOT1. Biochem Biophys Res Commun. 2019 Jan 29;509(1):241-248. doi: 10.1016/j.bbrc.2018.12.114. Epub 2018 Dec 24. PMID: 30591220. See more on PubMed
  • Wu Z, Wang L, Li G, Liu H, Fan F, Li Z, Li Y, Gao G. Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma. Mol Cell Biochem. 2013 Dec;384(1-2):263-8. doi: 10.1007/s11010-013-1805-5. PMID: 24122417. See more on PubMed
Related Products Docs